Dupixent® (dupilumab) Eosinophilic Esophagitis Trial Meets Both Co-Primary Endpoints

TARRYTOWN, N.Y. and PARIS , May 22, 2020 /PRNewswire/ — Dupixent demonstrated significant clinical and anatomic improvements, including the ability to swallow, in Part A of pivotal trial 69% reduction in disease symptoms with Dupixent, compared to 32% for placebo (p=0.0002) There are currently no

Original Source